Altered behaviors associated with LSD may be caused by a reduction in the normal communication between the hippocampus and visual cortex.
From microdosing to improve cognition, to treating a range of mental health disorders, researchers evaluate the rise in the use of psychedelics and their potential as medicines.
LSD increases social behaviors by activating 5-HTPA serotonin receptors and AMPA receptors in the prefrontal cortex, and the mTORC1 protein. Activating all three factors promoted social interactions. The findings suggest supervised LSD microdosing may help alleviate some of the social problems associated with ASD and other mental health disorders that impact social behaviors.
Researchers have uncovered the structure of psychedelic compounds when they actively bind to the 5-HT2A serotonin receptor on the surface of brain cells. The discovery could lead to the exploration of more precise compounds that offer the therapeutic effects of psychedelics for mental health disorders, but without the hallucinations.
Psilocybin reduces activity in the claustrum, an area of the brain believed to contribute to consciousness and sense of self. Researchers say the reduced activity may tie in with the reduced sense of self and ego often associated with psychedelic drug use. The study also reports psilocybin alters the way the claustrum communicates with brain areas involved in attention, decision making, auditory processing, and memory.
A recent case study report highlights the effects of LSD overdoses on three women, revealing the subjects experienced improvements in physical and mental health following their overdoses.
Study discussed the benefits of using psychedelics as an antidepressant option for those with depression.
DMT alters electrical activity in the brain. The compound significantly decreases alpha wave activity, the dominant rhythm associated with wakefulness, and increases theta waves, associated with dreaming. Overall brain activity becomes more chaotic and less predictable. The findings advance the understanding of the neurobiological underpinnings of immersive states of consciousness.
Numerous studies have linked controlled psychedelics to improvements in mental health conditions such as depression and PTSD. In March, the FDA approved Esketamine as a treatment for depression. However, with much stigma surrounding psychedelics, researchers question how many patients would take psychedelic medications if prescribed to them. According to a new study, 40% of people with no experience of psychedelics would be unlikely to take the prescription due to fears of 'brain damage' or a 'bad trip'.
Those who microdose psychedelics report improved mood, greater focus, and increased creativity. A new study looks at the positive outcomes of microdosing and suggests others look at potential long-term negative consequences of using psychedelics.
While many people report microdosing is beneficial to their mental wellbeing, researchers say more research needs to be conducted to evaluate the psychological and health implications of taking low-dose psychedelics.